| Literature DB >> 26987983 |
Christian M Wood1, Celine S Nicolas1, Sun-Lim Choi1, Erika Roman2, Ingrid Nylander2, Alberto Fernandez-Teruel3, Kalervo Kiianmaa4, Przemyslaw Bienkowski5, Trynke R de Jong6, Giancarlo Colombo7, Denis Chastagnier8, Keith A Wafford9, Graham L Collingridge1, Sheryl J Wildt10, Becky L Conway-Campbell11, Emma S J Robinson1, David Lodge12.
Abstract
Modulation of metabotropic glutamate 2 (mGlu2) receptor function has huge potential for treating psychiatric and neurological diseases. Development of drugs acting on mGlu2 receptors depends on the development and use of translatable animal models of disease. We report here a stop codon mutation at cysteine 407 in Grm2 (cys407*) that is common in some Wistar rats. Therefore, researchers in this field need to be aware of strains with this mutation. Our genotypic survey found widespread prevalence of the mutation in commercial Wistar strains, particularly those known as Han Wistar. Such Han Wistar rats are ideal for research into the separate roles of mGlu2 and mGlu3 receptors in CNS function. Previous investigations, unknowingly using such mGlu2 receptor-lacking rats, provide insights into the role of mGlu2 receptors in behaviour. The Grm2 mutant rats, which dominate some selectively bred lines, display characteristics of altered emotionality, impulsivity and risk-related behaviours and increased voluntary alcohol intake compared with their mGlu2 receptor-competent counterparts. In addition, the data further emphasize the potential therapeutic role of mGlu2 receptors in psychiatric and neurological disease, and indicate novel methods of studying the role of mGlu2 and mGlu3 receptors. This article is part of the Special Issue entitled 'Metabotropic Glutamate Receptors, 5 years on'.Entities:
Keywords: Alcohol preference; Anxiety; Emotionality; Grm2 mutation; Han Wistar rats; Metabotropic glutamate receptor; Selectively bred rats; Wistar rats; mGlu2
Mesh:
Substances:
Year: 2016 PMID: 26987983 DOI: 10.1016/j.neuropharm.2016.03.020
Source DB: PubMed Journal: Neuropharmacology ISSN: 0028-3908 Impact factor: 5.250